参考文献/References:
[1] de Bruijn SF, Stam J. Randomizsed, placebo-controlled trial of anticoagulant treatment with low-molecular-weight heparin for cerebral sinus thrombosis[J]. Stroke, 1999, 30: 484 - 488.
[2] 梁 瑛. 常用溶栓?抗凝药物[J]. 中国全科医学, 2003, 6: 857 - 858.
[3] Einhaupl KM, Villringer A, Meister W, et al. Heparin treatment in sinus venous thrombosis [J]. Lancet, 1991, 338: 597 - 600.
[4] Stam J, de Bruijn S, deVeber G. Anticoagulation for cerebral sinus thrombosis[J]. Stroke, 2003, 34: 1054 - 1055.
[5] 周 平, 李法琦. 常用抗血小板和抗凝药物在心脑血管疾病中的应用[J]. 心血管病学进展, 2004, 25: 338 - 341.
[6] 潘春梅, 向定成. 抗凝药比伐卢定国外临床应用进展[J]. 中国新药杂志, 2008, 17: 725 - 727.
[7] 王 珏, 程永德. 介入放射药物治疗学[M]. 北京: 科学出版社, 2009: 62.
[8] Weitz JI, Hirsh J, Samama MM, et al. New antithrombotic drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)[J]. Chest(6 supp 1), 2008, 133: 234S - 256S.
[9] 王拥军. 分层理念贯穿卒中防治始终[J]. 中国卒中杂志, 2009, 4: 10 - 12.
[10] 王鸿利. 抗凝药物和溶栓药物的临床应用和实验监测[J]. 内科急危重症杂志, 2001, 7: 184 - 189.
[11] Weimar C, Kraywinkel K, Maschke M, et al. Intravenous thrombolysis in geman stroke units before and after regulatory approval of recombinant tissue plasminogen activator[J]. Cerebrovasc Dis, 2006, 22: 429 - 431.
[12] Caplan LR. Thrombolysis 2004: the good, the bad, and the ugly[J]. Rev Neurol Dis, 2004, 1: 16 - 26.
相似文献/References:
[1]潘 曼,李海燕,齐戈尧.动脉粥样硬化患者介入术后服用抗血小板药物的依从性及其影响因素[J].介入放射学杂志,2022,31(09):917.
PAN Man,LI Haiyan,QI Geyao..The adherence of taking antiplatelet drugs in patients with atherosclerosis after receiving interventional therapy and analysis of its influencing factors[J].journal interventional radiology,2022,31(01):917.